Cell therapy uses viable healthy cells to replace, expand, and/or enhance a population of cells in order to achieve a therapeutic effect against a disease. The cell therapy field is rapidly expanding and claims the largest number of immuno-oncology therapies in clinical development. Chimeric antigen receptor (CAR) T-cell therapies lead the way; six treatments are already approved for hematological malignancies. Although CAR T cells dominate the pipeline, other cell therapies are beginning to gain traction, including tumor-infiltrating lymphocyte (TIL) therapies, T-cell receptor (TCR) therapies, and natural killer (NK) cell therapies. This Special Topics report provides a comprehensive view of the current cell therapy landscape and pipeline, with coverage of therapies in early-phase through late-phase development in a range of oncology indications.
Geographies: United States, EU5, Japan, and China.
Primary and secondary market research: In-depth interviews with six key opinion leaders (hematologist-oncologists and medical-oncologists); analysis of industry and company reports; peer-reviewed journals; pipeline databases; industry / scientific conferences; news; media
Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive pipeline analysis of the cell therapy landscape in relevant oncology indications.